American International Group, Inc. Mustang Bio, Inc. Transaction History

American International Group, Inc.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.58 - $1.13 $21,438 - $41,768	-36,963 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.73 - $1.81 $1,266 - $3,140	-1,735 Reduced 4.48%	36,963 $37,000
Q4 2021 Feb 11, 2022	BUY	$1.66 - $2.64 $1,005 - $1,599	606 Added 1.59%	38,698 $64,000
Q3 2021 Nov 12, 2021	SELL	$2.58 - $3.36 $2,337 - $3,044	-906 Reduced 2.32%	38,092 $102,000
Q2 2021 Aug 13, 2021	BUY	$2.7 - $3.81 $26,063 - $36,777	9,653 Added 32.89%	38,998 $129,000
Q1 2021 May 07, 2021	BUY	$3.02 - $5.16 $232 - $397	77 Added 0.26%	29,345 $97,000
Q4 2020 Feb 12, 2021	BUY	$2.66 - $4.18 $32,292 - $50,745	12,140 Added 70.88%	29,268 $111,000
Q3 2020 Nov 04, 2020	SELL	$3.01 - $3.88 $1,176 - $1,517	-391 Reduced 2.23%	17,128 $54,000
Q2 2020 Aug 12, 2020	BUY	$2.33 - $4.6 $2,420 - $4,779	1,039 Added 6.3%	17,519 $56,000
Q1 2020 May 04, 2020	SELL	$1.91 - $4.52 $1,818 - $4,303	-952 Reduced 5.46%	16,480 $44,000
Q4 2019 Feb 05, 2020	SELL	$2.57 - $4.08 $375 - $595	-146 Reduced 0.83%	17,432 $71,000
Q3 2019 Nov 08, 2019	SELL	$2.74 - $4.65 $337 - $571	-123 Reduced 0.69%	17,578 $57,000
Q2 2019 Aug 13, 2019	BUY	$2.66 - $6.28 $19,702 - $46,515	7,407 Added 71.95%	17,701 $65,000
Q1 2019 May 06, 2019	SELL	$2.95 - $5.61 $985 - $1,873	-334 Reduced 3.14%	10,294 $35,000
Q4 2018 Feb 13, 2019	SELL	$2.3 - $5.78 $188 - $473	-82 Reduced 0.77%	10,628 $31,000
Q3 2018 Nov 09, 2018	SELL	$5.71 - $7.58 $816 - $1,083	-143 Reduced 1.32%	10,710 $64,000
Q2 2018 Aug 08, 2018	BUY	$6.68 - $11.0 $72,498 - $119,383	10,853 New	10,853 $75,000

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $17.9M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.